How to buy Onconova Therapeutics stock (ONTX)

Our top picks for where to buy Onconova Therapeutics stock

Buy Onconova Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AS SEEN ON:

Onconova Therapeutics is a biotechnology business based in the US. Onconova Therapeutics shares (ONTX) are listed on the NASDAQ and all prices are listed in US Dollars. Onconova Therapeutics employs 16 staff and has a trailing 12-month revenue of around $226,000.

Onconova Therapeutics stock price (NASDAQ: ONTX)

Use our graph to track the performance of ONTX stocks over time.

Onconova Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.65 - $7.93
50-day moving average more info button	$0.82
200-day moving average more info button	$0.78
Wall St. target price	$8.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.96

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Onconova Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Onconova Therapeutics financials

Revenue TTM	$226,000
Gross profit TTM	$226,000
Return on assets TTM	-38.07%
Return on equity TTM	-84.3%
Profit margin	0%
Book value	$0.69
Market Capitalization more info button	$20.9 million

TTM: trailing 12 months

Onconova Therapeutics share dividends

We're not expecting Onconova Therapeutics to pay a dividend over the next 12 months.

Have Onconova Therapeutics's shares ever split?

Onconova Therapeutics's shares were split on a 1:15 basis on 20 May 2021 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Onconova Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Onconova Therapeutics shares which in turn could have impacted Onconova Therapeutics's share price.

Onconova Therapeutics share price volatility

Over the last 12 months, Onconova Therapeutics's shares have ranged in value from as little as $0.65 up to $7.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Onconova Therapeutics's is 1.349. This would suggest that Onconova Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Onconova Therapeutics overview

Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc.

Frequently asked questions

What percentage of Onconova Therapeutics is owned by insiders or institutions?
Currently 0.779% of Onconova Therapeutics shares are held by insiders and 7.949% by institutions. How many people work for Onconova Therapeutics?
Latest data suggests 16 work at Onconova Therapeutics. When does the fiscal year end for Onconova Therapeutics?
Onconova Therapeutics's fiscal year ends in December. Where is Onconova Therapeutics based?
Onconova Therapeutics's address is: 12 Penns Trail, Newtown, PA, United States, 18940 What is Onconova Therapeutics's ISIN number?
Onconova Therapeutics's international securities identification number is: US68232V8019 What is Onconova Therapeutics's CUSIP number?
Onconova Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68232V405